Enovis (NYSE:ENOV) Stock: Insider Angela Lalor Purchases 870 Shares

Key Points

• Director Angela Lalor bought 870 Enovis shares at an average price of $28.86, spending about $25,108. Her direct stake rose 2.69% to 33,243 shares.
• Enovis beat quarterly earnings expectations, reporting EPS of $0.88 versus the $0.77 consensus, while revenue of $558.73 million slightly exceeded estimates and rose 1.8% year over year.
• Analysts hold a “Moderate Buy” consensus rating, with an average price target of $38.62; shares traded at $27.63 in Thursday’s mid-day session.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Angela Lalor acquired 870 shares of the firm's stock in a transaction on Wednesday, November 11th. The stock was bought at an average price of $28.86 per share, with a total value of $25,108.20. Following the purchase, the director directly owned 33,243 shares of the company's stock, valued at $959,392.98. This represents a 2.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Enovis Stock Performance

Shares of ENOV stock traded down $0.92 during mid-day trading on Thursday, hitting $27.63. 1,153,270 shares of the stock were exchanged, compared to its average volume of 1,886,113. The stock's fifty day simple moving average is $20.36 and its two-hundred day simple moving average is $23.19. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. Enovis Corporation has a 12-month low of $16.70 and a 12-month high of $31.81. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 8.45 and a beta of 1.31.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.11. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business's quarterly revenue was up 1.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 EPS. On average, analysts forecast that Enovis Corporation will post 3.15 EPS for the current year.

Hedge Funds Weigh In On Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in ENOV. Private Management Group Inc. increased its position in Enovis by 31.3% in the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company's stock valued at $32,748,000 after acquiring an additional 427,347 shares during the period. Paradigm Capital Management Inc. NY lifted its position in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after acquiring an additional 732,917 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock worth $24,430,000 after acquiring an additional 287,687 shares during the period. Front Street Capital Management Inc. lifted its position in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP grew its stake in shares of Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company's stock valued at $13,752,000 after purchasing an additional 342,556 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the company. BMO Capital Markets set a $27.00 price target on Enovis in a research report on Tuesday, September 1st. Wells Fargo & Company boosted their price objective on Enovis from $33.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, November 6th. Wall Street Zen raised Enovis from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Weiss Ratings upgraded shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, November 2nd. Finally, Zacks Research raised shares of Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $38.62.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.